Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin, DH Munn… - Journal of Experimental …, 2013 - rupress.org
The cytotoxic T lymphocyte antigen-4 (CTLA-4)–blocking antibody ipilimumab results in
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin, DH Munn… - Journal for …, 2013 - search.proquest.com
The CTLA-4 blocking antibody ipilimumab results in durable responses in metastatic
melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for …
melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for …
Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin… - Journal of …, 2013 - augusta.elsevierpure.com
The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab results in
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
[PDF][PDF] Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin, DH Munn, JD Wolchok… - J. Exp. Med, 2013 - cyberleninka.org
The cytotoxic T lymphocyte antigen-4 (CTLA-4)–blocking antibody ipilimumab results in
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin… - The Journal of …, 2013 - pubmed.ncbi.nlm.nih.gov
The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab results in
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
RB Holmgaard, D Zamarin, DH Munn… - The Journal of …, 2013 - europepmc.org
The cytotoxic T lymphocyte antigen-4 (CTLA-4)–blocking antibody ipilimumab results in
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin, DH Munn… - Journal for …, 2013 - jitc.biomedcentral.com
The CTLA-4 blocking antibody ipilimumab results in durable responses in metastatic
melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for …
melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for …
Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin, DH Munn… - … for ImmunoTherapy of …, 2013 - Springer
The CTLA-4 blocking antibody ipilimumab results in durable responses in metastatic
melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for …
melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for …
[PDF][PDF] Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin, DH Munn, JD Wolchok… - J. Exp. Med, 2013 - Citeseer
The cytotoxic T lymphocyte antigen-4 (CTLA-4)–blocking antibody ipilimumab results in
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
durable responses in metastatic melanoma, though therapeutic benefit has been limited to a …
Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
RB Holmgaard, D Zamarin, DH Munn, JD Wolchok… - 2013 - jitc.bmj.com
The CTLA-4 blocking antibody ipilimumab results in durable responses in metastatic
melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for …
melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for …